Sana Biotechnology Raises $69M via ATM Sale, Boosts Cash Runway to Mid-2027
SANA•Sana Biotechnology sold 21,607,878 common shares via its ATM facility for net proceeds of approximately $69 million. Combined with a $25 million Mayo Clinic investment, the company has secured $94 million in new capital since Q1 end, extending its cash runway to mid-2027.
1. ATM Sale Details
Sana Biotechnology sold 21,607,878 shares of common stock through its at-the-market facility, generating net proceeds of approximately $69 million under its Form S-3ASR shelf registration filed March 3, 2026.
2. Combined Funding Round
An additional $25 million investment from Mayo Clinic brings total capital raised since the end of Q1 2026 to about $94 million, reflecting continued institutional support for the company’s engineered cell programs.
3. Extended Cash Runway
With this influx of new capital, Sana expects its cash runway to extend into mid-2027, providing operational funding for ongoing research, development, and early-stage clinical initiatives.
